Figures & data
Figure 1 Study design.
Table 1 Summary of baseline characteristics for the included patients overall and stratified by index therapy
Figure 2 Unadjusted (A) and adjusted (B–D) persistence to SC-TNFi therapy.
Abbreviations: ADA, adalimumab; CZP, certolizumab pegol; ETA, etanercept; GLM, Golimumab; SC-TNFi, subcutaneous tumor necrosis factor alpha inhibitors.
Table 2 Pre-matching baseline characteristics
Table 3 Post-matching baseline characteristics